You are here: Home: Audio Program Guide: BCU 6 | 2007 Audio: BCU 6 | 2007
 
  Go to interview with George W Sledge Jr, MD
Go to interview with William J Gradishar, MD
Go to interview with Lee S Schwartzberg, MD
Go to Faculty Tumor Panel segment
 


To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
George W Sledge Jr, MD
Ballve-Lantero Professor of Oncology
Professor of Medicine and Pathology
Melvin and Bren Simon Indiana University Cancer Center
Indianapolis, Indiana


 
  Click here to download the entire interview  
Track 1 Adjuvant trastuzumab: 2005-2007
Track 2 Analysis of NSABP-B-31: Multivariate risk model for cardiotoxicity after AC arrowpaclitaxel/trastuzumab
Track 3 Results of BCIRG 006: TCH as a nonanthracycline- containing alternative to adjuvant AC arrowtaxane/ trastuzumab
Track 4 Pitfalls in the assessment of HER2 status
Track 5 Relationship between polysomy of chromosome 17 and response to trastuzumab
Track 6 Treatment of patients with subcentimeter, node-negative, HER2-positive tumors

Track 7 Risk of congestive heart failure (CHF) with anthracycline regimens versus TCH
Track 8 The biologic drivers of dual HER2-positive, ER-positive disease
Track 9 BIG 2-06: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study
Track 10 Implications of random assignment to nontrastuzumab-containing therapy in ALTTO
Track 11 Clinical trials evaluating the combination of trastuzumab and lapatinib
Track 12 Prognostic and predictive utility of cMYC in HER2-positive disease
Track 13 Upregulation of VEGF in HER2-positive tumors
Track 14 Cardiac considerations with concomitant trastuzumab and bevacizumab
Track 15 Lessons learned from ECOG-E2100: Paclitaxel with or without bevacizumab as first-line therapy
Track 16 Optimal duration of biologic therapy with trastuzumab or bevacizumab
Track 17 XCaliBr study of capecitabine with bevacizumab as first-line therapy
Track 18 Impact of adjuvant taxane exposure on future therapy selection
Track 19 Phase II trial of docetaxel with or without axitinib for metastatic breast cancer
Track 20 Targeting the endothelial cell with chemotherapy and bevacizumab
Track 21 Continuation of bevacizumab beyond disease progression
Track 22 ECOG-E5103: Adjuvant AC and paclitaxel with or without bevacizumab in early breast cancer
Track 23 Cardiac event monitoring in ECOG-E2104 pilot adjuvant trial of AC and paclitaxel with bevacizumab
Track 24 Incorporation of Oncotype DX™-defined risk assessment into E5103
Track 25 Treatment with weekly paclitaxel in E5103
Track 26 Reporting adjuvant bevacizumab trials in colon cancer: Impact on recruitment to E5103
Track 27 Dosing of bevacizumab
     
Gradishar, MD William J Gradishar, MD
Director, Breast Medical Oncology
Professor of Medicine
Robert H Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois
  
  Click here to download the entire interview  
Track 1 Development of nab paclitaxel
Track 2 Randomized Phase II comparison of nab paclitaxel versus docetaxel as first-line therapy
Track 3 Impact of independent radiology review on trial endpoints
Track 4 Tolerability of nab paclitaxel
Track 5 Incidence and resolution of nab paclitaxel-associated neuropathy
Track 6 Planned clinical trials of nab paclitaxel in breast cancer

Track 7 Rationale for combining nab paclitaxel with bevacizumab
Track 8 Substitution of nab paclitaxel for other taxanes
Track 9 Avoidance of steroid premedication with nab paclitaxel
Track 10 Nab paclitaxel in the adjuvant setting
Track 11 Capecitabine with bevacizumab as first- or second-line therapy
Track 12 Subgroup analysis of XCaliBr by hormone receptor status
Track 13 Studying the oral platinum satraplatin in breast cancer
audio
Track 14 Neoadjuvant lapatinib in patients with HER2-positive disease
audio
Track 15 EFECT: Fulvestrant versus exemestane after a nonsteroidal aromatase inhibitor in postmenopausal women with advanced breast cancer
audio
Track 16 Total estrogen blockade: Combining fulvestrant with aromatase inhibitors
audio
Track 17 Rationale for evaluating fulvestrant in the adjuvant setting
audio
Track 18 Fulvestrant and the premenopausal patient
audio
Track 19 Preclinical rationale for fulvestrant in ER-positive, HER2-positive breast cancer
audio
Track 20 Randomized Phase II study of paclitaxel with or without sorafenib as first-line therapy
audio
     

     
Schwartzberg, MD Lee S Schwartzberg, MD
Medical Director, The West Clinic
Clinical Professor of Medicine, University of Tennessee School of Medicine
Memphis, Tennessee
  
  Click here to download the entire interview  
Track 1 Innovative techniques to assess patient symptomatology
Track 2 The tablet computer-based Patient Care Monitor™ (PCM)
Track 3 Availability of the PCM to physicians in practice
Track 4 Overuse of steroid premedication with nab paclitaxel
Track 5 Incorporation of nab paclitaxel into clinical practice
Track 6 Impetus for the development of the Accelerated Community Oncology Research Network (ACORN)

Track 7 Use of technology to facilitate research in ACORN
Track 8 Implications of investigator remuneration for clinical trial participation
Track 9 Investigator- and industry-initiated clinical trials in ACORN
Track 10 ACORN Phase II study of capecitabine with nab paclitaxel as first-line therapy
Track 11 Selection of first-line therapy for metastatic breast cancer
audio
Track 12 Investigating sorafenib and sunitinib in breast cancer
audio
Track 13 ACORN trial of fulvestrant with capecitabine for patients with hormone receptor-positive
advanced breast cancer
audio
Track 14 Combination chemotherapy and endocrine therapy for patients with metastatic breast cancer
audio
Track 15 Practical integration of capecitabine in the breast cancer treatment algorithm
audio
Track 16 Fulvestrant loading dose
audio

     

Faculty Tumor Panel

Burstein, MD

Harold J Burstein, MD, PhD
Assistant Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts

 O'Shaughnessy

Joyce O’Shaughnessy, MD
Co-Director, Breast Cancer Research Program
Baylor-Charles A Sammons Cancer Center
Texas Oncology, PA
US Oncology
Dallas, Texas
 
  Click here to download the entire segment  
Track 1 Case discussion: A woman in her midforties, status-post neoadjuvant dose-dense AC arrow T for locally advanced triple-negative breast cancer, who presents with significant residual tumor at the time of surgery
Track 2 Adjuvant therapy in the setting of an incomplete pathologic response
Track 3 Correlation between ethnicity and triple-negative breast cancer
Track 4 Treatment alternatives for triple-negative disease
Track 5 Combining chemotherapy with bevacizumab
Track 6 Phase II trial of irinotecan/carboplatin with or without cetuximab

Track 7 Clinical trials of DNA-damaging agents
Track 8 Mastectomy for local control in patients with documented metastatic spread
Track 9 Case discussion: A woman with a history of lobular breast cancer treated two years prior with definitive surgery, adjuvant AC arrow T and continuous anastrozole who presents with an isolated colon metastasis identified via routine colonoscopy
Track 10 Assessment of rising tumor markers in patients progressing on adjuvant therapy
Track 11 Clinical experience with Halotestin® for progressive, hormone-responsive breast cancer
audio
Track 12 Hormone therapy for lobular breast cancer
audio
Track 13 Case discussion: A premenopausal woman with a large hormone receptor-positive, HER2-negative breast tumor and de novo bone metastases
audio
Track 14 Fulvestrant dosing strategies
audio
Track 15 The unique natural history of hormone receptor-positive breast cancer
audio
Track 16 A place for fulvestrant in the adjuvant setting
audio
Track 17 Case discussion: A young woman with strongly serum HER2-positive, progressive bone and visceral metastases after treatment for HER2 FISH-negative, Grade III breast cancer
Track 18 Serum conversion of HER2 status